// App-Quantinova.ai

5166 : Blood-based biomarker analysis for predicting efficacy of definitive concurrent chemoradiotherapy and durvalumab consolidation in patients with unresectable locally advanced non-small cell lung cancer

Researchers

Presenter

  • Cheol-Kyu Park

Principal Investigators

  • Hwa-Kyung Park

  • Hyung-Joo Oh

  • Hyun-Ju Cho

  • In-Jae Oh

  • Young-Chul Kim

Medical Centers

  • Chonnam National University Medical School and Hwasun hospital, Hwasun, Jeonnam, Korea, Republic of

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating tumor cells

  • Protein Tyrosine Phosphatase, Receptor Type C

  • Programmed death-ligand 1

  • Epithelial Cell Adhesion Molecule

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved